Development of molecular target radiation therapy from molecular target imaging

从分子靶标成像发展分子靶标放射治疗

• 批准号: 23659582
• 负责人: MAGATA Yasuhiro
• 金额: $ 2.25万
• 依托单位: Hamamatsu University School of Medicine
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Challenging Exploratory Research
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23659582/
• 关键词: 放射線内用療法; 分子標的薬; イメージング; 放射性医薬品; がん; I-131; 分子標的; 低分子; EGFR-TK

This study is a trial to develop a novel concept which makes molecular target drug for cancer enable radiation therapy . This concept can allow not only molecular target imaging and also molecular target radiation therapy. In this study, we use our new molecular imaging compound, PYK for EGFR-TK. This compound has a great potential for in vivo imaging for EGFR-TK. In conclusion, molecular target radiation therapy might be achieved although additional compounds are required to improve target uptake or target to non-target ratio.

本研究是一项尝试，以开发一种新的概念，使分子靶向药物的癌症，使放射治疗。这一概念不仅可以允许分子靶向成像，还可以允许分子靶向放射治疗。在这项研究中，我们使用我们的新的分子成像化合物，PYK的EGFR-TK。该化合物具有用于EGFR-TK的体内成像的巨大潜力。总之，尽管需要额外的化合物来改善靶向摄取或靶向与非靶向的比率，但分子靶向放射治疗是可能实现的。